Livzon/Kanova’s Lecankitug Gets China Approval After Beating Secukinumab in Phase 3 Psoriasis Trial
China’s National Medical Products Administration (NMPA) has approved lecankitug (LZM012/XKH004), an IL-17A/IL-17F-targeting monoclonal antibody jointly developed by Livzon Pharmaceutical Group and Beijing Kanova Biopharmaceutical, for the treatment of…